The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world outcomes by race in patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Final analysis results from the informCLL registry.
 
Jacqueline Claudia Barrientos
Honoraria - Janssen
Consulting or Advisory Role - AstraZeneca; BeiGene; MEI Pharma; Pharmacyclics
Research Funding - AstraZeneca (Inst); Merck (Inst)
 
Jeff Porter Sharman
Employment - US Oncology Network
Consulting or Advisory Role - Abbvie; Acerta Pharma/AstraZeneca; Beigene; Beigene; Bristol-Myers Squibb; Genentech; Janssen Oncology; Lilly; Merck
Research Funding - Acerta Pharma (Inst); Celgene (Inst); Genentech (Inst); Gilead Sciences (Inst); Merck (Inst); Pharmacyclics (Inst); Seagen (Inst); Takeda (Inst); TG Therapeutics (Inst)
 
Meghan E. Gutierrez
No Relationships to Disclose
 
Linda Wu
Employment - Asieris Pharmaceuticals
Leadership - Asieris Pharmaceuticals
Stock and Other Ownership Interests - Asieris Pharmaceuticals
 
Zaina P. Qureshi
Employment - Johnson & Johnson; Merck
Stock and Other Ownership Interests - Merck
 
Anat Raz
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Vincent Girardi
Employment - Everest Clinical Research
Other Relationship - Abbvie
 
Maoko Naganuma
Employment - Pharmacyclics
Stock and Other Ownership Interests - Abbvie
 
Nilanjan Ghosh
Consulting or Advisory Role - Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca; Beigene; Bristol-Myers Squibb; Genmab; Gilead Sciences; Incyte; Karyopharm Therapeutics; Loxo/Lilly; Novartis; Pharmacyclics/Janssen; Roche/Genentech; Seagen; TG Therapeutics
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Epizyme; Kite/Gilead; Pharmacyclics/Janssen
Research Funding - Abbvie (Inst); Bristol-Myers Squibb/Celgene (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Morphosys (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst)